Apogee Therapeutics, Inc.
APGE
Rangering i aksjer
#2366
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Aksjekurs
$135.07
Sist synkronisert: 2026-09-04
Markedsverdi
$8.36B
Endring (1 dag)
0.00%
Endring (1 år)
137.21%
Land
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategori
Healthcare
Antall utestående aksjer for Apogee Therapeutics, Inc. (APGE)
Antall utestående aksjer per June 2026: 75.44M
Ifølge Apogee Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 75.44M. Ved slutten av December 2023 hadde selskapet 50.66M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Apogee Therapeutics, Inc. (APGE) fra 2022 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 75.44M | 36.69% |
| 2024 | 55.19M | 8.96% |
| 2023 | 50.66M | -0.04% |
| 2022 | 50.67M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 236.54% |
US
|
|
| 396.00M | 424.90% |
US
|
|
| 478.91M | 534.80% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -17.57% |
NL
|
